title: Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.
authors.forename: C
authors.initials: C
authors.lastname: Charbonneau
authors.forename: R
authors.initials: R
authors.lastname: Sandin